Advertisement

Selection of the Best Treatment for Osteoporosis

  • Nelson B. Watts
Part of the Clinical Perspectives in Obstetrics and Gynecology book series (CPOG)

Abstract

Certain general measures are appropriate for all people, whether they have osteoporosis or not (Table 17.1). These include an adequate intake of calcium and vitamin D, an active life style, and avoidance of toxins (e.g., cigarettes, alcohol). Medications that increase bone loss (e.g., thyroid hormones in excessive doses, glucocorticoids in pharmacologic doses, furosemide, anticonvulsants, etc.), if necessary, should be used in the lowest effective doses and monitored regularly.

Keywords

Bone Mass Vertebral Fracture Bone Mineral Content Estrogen Treatment Sodium Fluoride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Matkovic V, Fontana D, Tominac C, Lehman J, Chesnut C. Influence of calcium on peak bone mass: a pilot study. J Bone Mineral Res. 1986; 1 (suppl 1): 168.Google Scholar
  2. 2.
    Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med. 1987; 316: 173–177.PubMedCrossRefGoogle Scholar
  3. 3.
    Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med. 1990; 323: 878–883.PubMedCrossRefGoogle Scholar
  4. 4.
    Schwartzman MS, Franck WA. Vitamin D toxicity complicating the treatment of senile, postmenopausal, and glucocorticoid-induced osteoporosis: four case reports and a critical commentary on the use of vitamin D in these disorders. Am J Med. 1987; 82: 224–230.PubMedCrossRefGoogle Scholar
  5. 5.
    Ott SM, Chesnut CH III. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989; 110: 267–274.PubMedGoogle Scholar
  6. 6.
    Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med. 1990; 113: 649–655.PubMedGoogle Scholar
  7. 7.
    Drinkwater BL, Nilson K, Chesnut CH III, Bremner WJ, Shainholtz S, Southworth MB. Bone mineral content of amenorrheic and eumenorrheic athletes. N Engl J Med. 1984; 311: 277–281.PubMedCrossRefGoogle Scholar
  8. 8.
    Dalsky GP, Stocke KS, Ehsani AA, Slato-polsky E, Lee WC, Birge SJ Jr. Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med. 1988; 108: 824–828.PubMedGoogle Scholar
  9. 9.
    Orwoll ES, Ferar J, Oviatt SK, McClung MR, Huntington K. The relationship of swimming exercise to bone mass in men and women. Arch Intern Med. 1989; 149: 2197–2200.PubMedCrossRefGoogle Scholar
  10. 10.
    Greenspan SL, Greenspan FS, Resnick NM, Bloci JE, Friedlander A, Genant HK. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy. Am J Med. 1991; 91: 5–14.PubMedCrossRefGoogle Scholar
  11. 11.
    Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352–364.PubMedGoogle Scholar
  12. 12.
    Grisso JA, Kelsey JL, Strom BL, et al. Risk factors for falls as a cause of hip fracture in women. N Engl J Med. 1991; 324: 1326–1331.PubMedCrossRefGoogle Scholar
  13. 13.
    Steinberg KK, Freni-Titulaer LW, DePuey EG, et al. Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab. 1989; 69: 533–539.PubMedCrossRefGoogle Scholar
  14. 14.
    Prior JC, Vigna YM, Schechter MT, Burgess AE. Spinal bone loss and ovulatory disturbances. N Engl J Med. 1990; 323: 1221–1227.PubMedCrossRefGoogle Scholar
  15. 15.
    Tosteson ANA, Rosenthal DI, Melton LJ III, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med. 1990; 113: 594–603.PubMedGoogle Scholar
  16. 16.
    Hillner BE, Hollenberg JP, Pauker SG. Postmenopausal estrogens in prevention of osteoporosis. Benefits virtually without risk if cardiovascular effects are considered. Am J Med. 1986; 80: 1115–1127.PubMedCrossRefGoogle Scholar
  17. 17.
    Wallach S. Calcitonin treatment of osteoporosis. In: Pak CYC, ed. Pharmacological Treatment of Endocrinopathies. Bone Disease, Kidney Stones, and Related Disorders. Progress in Basic and Clinical Pharmacology, 5. Basel: Karger; 1991: 108–124.Google Scholar
  18. 18.
    Civitelli R, Gonnelli S, Zacchei F, et al. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. Clin Invest. 1988; 82: 1268–1274.CrossRefGoogle Scholar
  19. 19.
    Lindsay R, Tohme, JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol. 1990; 76: 290–295.PubMedGoogle Scholar
  20. 20.
    Fleisch H. Bisphosphonates—phistory and experimental basis. Bone. 1987;8 (suppl 1):S23- S28.PubMedCrossRefGoogle Scholar
  21. 21.
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990; 322: 1265–1271.PubMedCrossRefGoogle Scholar
  22. 22.
    Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990; 323: 73–79.PubMedCrossRefGoogle Scholar
  23. 23.
    Smith ML, Fogelman I, Hart DM, Scott E, Bevan J, Leggate I. Effect of etidronate di-sodium on bone turnover following surgical menopause. CalcifTiss Int. 1989; 44: 74–79.CrossRefGoogle Scholar
  24. 24.
    Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-l-hydroxypropylidene)-l, 1-bisphosphonate (APD). Lancet. 1988;i:143–146.CrossRefGoogle Scholar
  25. 25.
    Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990; 322: 802–809.PubMedCrossRefGoogle Scholar
  26. 26.
    Frost HM. Treatment of osteoporosis by manipulation of coherent bone cell populations. Clin Orthop Rel Res. 1979; 143: 227–244.Google Scholar
  27. 27.
    LaCroix AZ, Weihpahl J, White LR, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med. 1990; 322: 286–290.PubMedCrossRefGoogle Scholar
  28. 28.
    Felson DT, Sloutskis D, Anderson JJ, Anthony JJ, Kiel, DP. Thiazide diuretics and the risk of hip fracture: results from the Framing-ham study. JAMA. 265: 370–373, 1991.PubMedCrossRefGoogle Scholar
  29. 29.
    Wasnich RD, Ross PD, Heilbrun LK, Vogel JM, Yano K, Benfante RJ. Differential effects of thiazide and estrogen upon bone mineral content and fracture prevalence. Obstet Gynecol. 1986; 67: 457–462.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • Nelson B. Watts

There are no affiliations available

Personalised recommendations